ZA200908725B - Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperdinyl-carbonyl-pyrrolo{3,2,1-jk][1,4]benzodiazepine - Google Patents

Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperdinyl-carbonyl-pyrrolo{3,2,1-jk][1,4]benzodiazepine

Info

Publication number
ZA200908725B
ZA200908725B ZA2009/08725A ZA200908725A ZA200908725B ZA 200908725 B ZA200908725 B ZA 200908725B ZA 2009/08725 A ZA2009/08725 A ZA 2009/08725A ZA 200908725 A ZA200908725 A ZA 200908725A ZA 200908725 B ZA200908725 B ZA 200908725B
Authority
ZA
South Africa
Prior art keywords
pyrine
piperdinyl
potentiation
benzodiazepine
pyrrol
Prior art date
Application number
ZA2009/08725A
Other languages
English (en)
Inventor
Venkatraghavan Vasudevan
Thomas Albert Engler
Marcio Chedid
Aktham Aburub
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200908725(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200908725B publication Critical patent/ZA200908725B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2009/08725A 2007-07-02 2009-12-08 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperdinyl-carbonyl-pyrrolo{3,2,1-jk][1,4]benzodiazepine ZA200908725B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Publications (1)

Publication Number Publication Date
ZA200908725B true ZA200908725B (en) 2011-02-23

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/08725A ZA200908725B (en) 2007-07-02 2009-12-08 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperdinyl-carbonyl-pyrrolo{3,2,1-jk][1,4]benzodiazepine

Country Status (22)

Country Link
US (2) US8318713B2 (enExample)
EP (1) EP2173348B1 (enExample)
JP (2) JP5551589B2 (enExample)
KR (1) KR101230085B1 (enExample)
CN (2) CN102772416A (enExample)
AR (1) AR067112A1 (enExample)
AU (1) AU2008270732B2 (enExample)
BR (1) BRPI0813789A2 (enExample)
CA (1) CA2691587C (enExample)
CL (2) CL2008001848A1 (enExample)
EA (2) EA023697B1 (enExample)
ES (1) ES2561202T3 (enExample)
IL (2) IL202237A (enExample)
MA (1) MA31677B1 (enExample)
MX (1) MX2009013449A (enExample)
MY (1) MY154472A (enExample)
NZ (1) NZ581355A (enExample)
PE (1) PE20090838A1 (enExample)
TW (1) TWI428132B (enExample)
UA (1) UA97400C2 (enExample)
WO (1) WO2009006043A2 (enExample)
ZA (1) ZA200908725B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
JP5699129B2 (ja) * 2009-04-14 2015-04-08 イーライ リリー アンド カンパニー 造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
WO2013044219A1 (en) * 2011-09-22 2013-03-28 Bind Biosciences Methods of treating cancers with therapeutic nanoparticles
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
AU2017386417B2 (en) * 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CA3222225A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ES2276048T3 (es) * 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
WO2004026867A2 (en) * 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
CA2569091A1 (en) 2004-07-09 2006-01-19 Agency For Science, Technology And Research Modulation of gsk-3.beta. and method of treating proliferative disorders
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
JP5551589B2 (ja) 2014-07-16
CL2011003046A1 (es) 2012-08-24
US20130039996A1 (en) 2013-02-14
MX2009013449A (es) 2010-01-15
CA2691587A1 (en) 2009-01-08
EA201070085A1 (ru) 2010-04-30
IL202237A (en) 2014-05-28
EA023697B1 (ru) 2016-07-29
IL218443A0 (en) 2012-04-30
JP2010532364A (ja) 2010-10-07
CN102772416A (zh) 2012-11-14
AR067112A1 (es) 2009-09-30
TW200911272A (en) 2009-03-16
MA31677B1 (fr) 2010-09-01
AU2008270732A1 (en) 2009-01-08
NZ581355A (en) 2012-04-27
CN101743005B (zh) 2013-06-12
HK1141236A1 (zh) 2010-11-05
CL2008001848A1 (es) 2009-05-29
WO2009006043A2 (en) 2009-01-08
PE20090838A1 (es) 2009-07-02
ES2561202T3 (es) 2016-02-25
EP2173348A2 (en) 2010-04-14
KR101230085B1 (ko) 2013-02-05
US8318713B2 (en) 2012-11-27
TWI428132B (zh) 2014-03-01
US20100166884A1 (en) 2010-07-01
JP2014114297A (ja) 2014-06-26
US8648063B2 (en) 2014-02-11
BRPI0813789A2 (pt) 2014-12-30
CN101743005A (zh) 2010-06-16
AU2008270732B2 (en) 2013-01-31
MY154472A (en) 2015-06-30
CA2691587C (en) 2013-09-24
WO2009006043A3 (en) 2009-04-16
UA97400C2 (uk) 2012-02-10
EA201201155A1 (ru) 2014-11-28
IL202237A0 (en) 2010-06-16
EA018447B1 (ru) 2013-08-30
KR20100017984A (ko) 2010-02-16
EP2173348B1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
IL202237A0 (en) Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo[1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyl-pyrrolo[3,2,1-jk][1,4]benzodiazepine
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
ZA201201397B (en) Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
ZA201104853B (en) 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
ZA201202718B (en) Pyrrolo[2,3-d]pyrimidine compounds
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
IL215158A0 (en) Imidazo [2,1-b] [1,3,4] thiadiazole derivatives
IL198761A0 (en) 7-substituted purine derivatives for immunosuppression
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
ZA201106625B (en) Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
SI2124944T1 (sl) Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
EP2142542A4 (en) NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
ZA201101550B (en) 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
IL202471A0 (en) Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
ZA200907416B (en) Pyrimido [4,5-D] azepine derivatives as 5-HT2C agonists
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
ZA201008178B (en) Imidazo [2,1-b]quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
EP2511276A4 (en) Pyrrolo [2,3-D] pyrimidine derivative
IL194384A0 (en) Process for preparaing 6,7-dihydro-5h-imidazo[1,5-a]pyridin-8-one